Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Open in Screener

BLUE

Bluebird bio Inc

May 17 • 04:00PM ET

1.03

Dollar change -0.02
Percentage change -1.90	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN IBB VTWO IWC DFAT ITOT GNOM

Index	RUT	P/E	-	EPS (ttm)	-0.74	Insider Own	1.51%	Shs Outstand	192.74M	Perf Week	-2.83%
Market Cap	198.52M	Forward P/E	-	EPS next Y	-1.05	Insider Trans	-1.21%	Shs Float	189.83M	Perf Month	8.08%
Income	-91.17M	PEG	-	EPS next Q	-0.43	Inst Own	55.24%	Short Float	16.78%	Perf Quarter	0.98%
Sales	21.73M	P/S	9.14	EPS this Y	11.53%	Inst Trans	7.50%	Short Ratio	3.87	Perf Half Y	-68.69%
Book/sh	2.08	P/B	0.50	EPS next Y	32.83%	ROA	-16.08%	Short Interest	31.86M	Perf Year	-73.59%
Cash/sh	0.95	P/C	1.08	EPS next 5Y	45.80%	ROE	-47.81%	52W Range	0.85 - 5.53	Perf YTD	-25.36%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-20.06%	52W High	-81.37%	Beta	0.87
Dividend TTM	-	Quick Ratio	1.42	Sales past 5Y	120.04%	Gross Margin	-15.86%	52W Low	21.03%	ATR (14)	0.10
Dividend Ex-Date	-	Current Ratio	1.55	EPS Y/Y TTM	87.79%	Oper. Margin	-1523.91%	RSI (14)	48.72	Volatility	8.40% 9.92%
Employees	-	Debt/Eq	1.36	Sales Y/Y TTM	322.60%	Profit Margin	-419.62%	Recom	2.79	Target Price	3.89
Option/Short	Yes / Yes	LT Debt/Eq	1.04	EPS Q/Q	29.93%	Payout	-	Rel Volume	0.22	Prev Close	1.05
Sales Surprise	-3.44%	EPS Surprise	-6.05%	Sales Q/Q	17353.52%	Earnings	May 09 BMO	Avg Volume	8.24M	Price	1.03
SMA20	5.10%	SMA50	-10.58%	SMA200	-54.42%	Trades		Volume	1,845,271	Change	-1.90%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-11-23	Downgrade	HSBC Securities	Hold → Reduce
Dec-08-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$3 → $7
Oct-17-23	Initiated	Cantor Fitzgerald	Neutral
Sep-06-23	Initiated	HSBC Securities	Buy	$4.21
Jul-19-23	Upgrade	BofA Securities	Neutral → Buy	$6 → $10
Jun-01-23	Upgrade	Barclays	Equal Weight → Overweight	$7 → $8
Apr-28-23	Initiated	JP Morgan	Overweight	$7
Mar-07-23	Initiated	Robert W. Baird	Outperform	$10
Aug-05-22	Upgrade	Barclays	Underweight → Equal Weight
Aug-02-22	Upgrade	Raymond James	Mkt Perform → Outperform	$8
Apr-06-22	Downgrade	Cowen	Outperform → Market Perform
Mar-07-22	Downgrade	Barclays	Equal Weight → Underweight	$4
Nov-08-21	Reiterated	Wells Fargo	Equal Weight	$25 → $16
Nov-08-21	Reiterated	Wedbush	Neutral	$22 → $11
Nov-08-21	Reiterated	RBC Capital Mkts	Sector Perform	$26 → $14
Nov-08-21	Reiterated	Canaccord Genuity	Hold	$20 → $15
Nov-08-21	Reiterated	Barclays	Equal Weight	$20 → $13
Nov-08-21	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$11
Nov-08-21	Downgrade	Goldman	Neutral → Sell	$23 → $10
Aug-10-21	Resumed	William Blair	Mkt Perform

Show Previous Ratings

May-17-24 03:46PM	BLUE vs. CRSP: Why Are These Stocks Moving in Opposite Directions? (TipRanks)
May-16-24 09:22AM	Is Bluebird Bio Stock a Buy? (Motley Fool)
May-14-24 11:24AM	Shareholders of bluebird bio, Inc. Should Contact Levi & Korsinsky Before May 28, 2024 to Discuss Your Rights BLUE (GlobeNewswire)
May-10-24 03:36PM	bluebird bio Inc (BLUE) Q1 2024 Earnings: Surpasses Revenue Expectations with Strategic Focus ... (GuruFocus.com) -5.36%
01:34PM	bluebird (BLUE) Tops on Q1 Sales, Zynteglo Progresses Well (Zacks)
07:00AM	Loading…
May-09-24 07:00AM	bluebird bio Reports First Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance (Business Wire) +14.92%
May-07-24 12:40PM	bluebird bio, Inc. Sued for Securities Law Violations Investors Should Contact Levi & Korsinsky Before May 28, 2024 to Discuss Your Rights BLUE (GlobeNewswire)
May-06-24 07:05AM	bluebird bio Announces First Quarter 2024 Results Call Date and Upcoming Investor Events (Business Wire) +11.14%
07:00AM	bluebird bio Announces Completion of First Cell Collection for LYFGENIA Gene Therapy (Business Wire)
Apr-26-24 04:43PM	bluebird bio Gets Nasdaq Notice for Late Filing of Annual Report (MT Newswires)
04:05PM	bluebird bio Announces Receipt of Expected Notice from Nasdaq (Business Wire)
Apr-16-24 02:05PM	bluebird (BLUE) Underperforms Industry YTD Amid Challenges (Zacks)
Apr-15-24 08:15AM	Is Bluebird Bio Stock a Buy? (Motley Fool) -6.36%
Apr-13-24 04:22PM	Better Buy: Bluebird Bio Vs. Novavax (Motley Fool)
Apr-11-24 08:30AM	Is This Beaten-Down Stock a Good Acquisition Target? (Motley Fool)
08:00AM	Loading…
08:00AM	bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-02-24 11:33AM	bluebird bio, Inc. (NASDAQ:BLUE) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-29-24 05:20AM	Bluebird Bio Stock Has 138% Upside, According to 1 Wall Street Analyst (Motley Fool)
Mar-27-24 11:37AM	bluebird (BLUE) Misses on Q4 Revenues, Provides Portfolio Updates (Zacks) +13.75%
10:00AM	Earnings Preview: Bluebird Bio (BLUE) Q4 Earnings Expected to Decline (Zacks)
Mar-26-24 07:01AM	bluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance (Business Wire) -11.76%
Mar-25-24 04:05PM	bluebird bio to Host Fourth Quarter and 2023 Annual Results Conference Call (Business Wire)
Mar-19-24 07:44AM	bluebird (BLUE) Gets $175 Million Loan From Hercules, Shares Up (Zacks)
Mar-18-24 06:05PM	Why Bluebird Bio Stock Flew Higher Than the Market Today (Motley Fool)
08:00AM	bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital (Business Wire)
Mar-13-24 07:50AM	Is Bluebird Bio Stock a Buy Now? (Motley Fool)
Mar-11-24 08:00AM	bluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy (Business Wire) -7.33%
Mar-05-24 06:56PM	Why Bluebird Bio Stock Dived Into the Red on Tuesday (Motley Fool) -9.15%
Jan-27-24 07:28AM	If You Invested $1,000 in Bluebird Bio in 2019, This Is How Much You Would Have Today (Motley Fool)
05:27AM	5 Best 52-Week Low Stocks To Buy Now (Insider Monkey)
06:55AM	Loading…
Jan-10-24 06:55AM	2 Red Flags for Bluebird Bio Stock (Motley Fool)
Jan-08-24 08:00AM	bluebird bio Provides Update on Commercial Launch Progress, Program Milestones, and 2024 Financial Outlook (Business Wire)
Jan-04-24 03:32PM	Bluebirds Plans to Win in Sickle Cell Come Into Focus (The Wall Street Journal) +5.84%
Jan-03-24 07:15AM	Better Risky Investment: Bluebird Bio vs. Shiba Inu (Motley Fool) -6.80%
Jan-02-24 08:00AM	bluebird bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire) +6.52%
Dec-26-23 08:00AM	Should You Invest in Bluebird Bio Right Now? (Motley Fool)
Dec-24-23 07:39AM	If You Invested $10,000 in Bluebird Bio In 2021, This Is How Much You Would Have Today (Motley Fool)
Dec-23-23 07:30AM	1 Green Flag and 1 Red Flag for Bluebird Bio Stock (Motley Fool)
Dec-22-23 08:45AM	3 Money-Saving Tricks for Investing in Biotech Stocks in 2024 (Motley Fool)
Dec-20-23 02:23PM	Bluebird Bio Stock Plunges (Barrons.com) -45.68%
01:54PM	Bluebird Bio Stock Is in Free Fall Weeks After a Landmark FDA Approval. Heres Why. (Barrons.com)
Dec-19-23 09:41PM	bluebird bio, Inc. Announces Pricing of $125 Million Public Offering of Common Stock (Business Wire) -20.33%
Dec-18-23 04:01PM	bluebird bio, Inc. Announces Proposed Public Offering of Common Stock (Business Wire) -6.73%
Dec-15-23 11:14AM	Down 30% in a Week, What in the World Is Going On With Bluebird Bio Stock? (Motley Fool)
Dec-11-23 05:43AM	Is CRISPR Therapeutics a Good Stock to Buy Following Approval of Its First Drug? (Motley Fool) +7.34%
Dec-10-23 12:02PM	Long-Term Data Presented at ASH Support beti-cel as a Potentially Curative Gene Therapy for -Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels (Business Wire)
Dec-09-23 11:31AM	Long-term Follow-up Data From bluebirds Gene Therapy Program in Sickle Cell Disease Support Durable, Potentially Curative Benefits Through Stable Production of Anti-Sickling Adult Hemoglobin and Resolution of Vaso-Occlusive Events (Business Wire)
Dec-08-23 01:45PM	FDA Approves Worlds First Crispr Gene-Editing Drug for Sickle-Cell Disease (The Wall Street Journal) -40.54%
01:01PM	bluebird bio Details Plans for the Commercial Launch of LYFGENIA Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events (Business Wire)
12:35PM	bluebird bio Announces FDA Approval of LYFGENIA (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events (Business Wire)
Dec-07-23 11:30AM	Bluebird (BLUE) Up 48.2% Since Last Earnings Report: Can It Continue? (Zacks)
08:45AM	These 2 Stocks Could Be About to Soar: Are They Buys? (Motley Fool)
Dec-01-23 07:41AM	bluebird bio (BLUE) Stock Gains 25.6% in a Month: Here's How (Zacks) +11.52%
Nov-29-23 02:28PM	If You Can Only Buy One Biotech Stock in December, It Better Be One of These 3 Names (InvestorPlace)
Nov-26-23 04:44PM	2 Biotech Stocks That Could Soar in December (Motley Fool)
Nov-24-23 07:00AM	Gene Editing Will Change Medicineand Maybe Health Investing Too (The Wall Street Journal)
Nov-08-23 03:39PM	bluebird bio, Inc. (NASDAQ:BLUE) Q3 2023 Earnings Call Transcript (Insider Monkey) -7.91%
Nov-07-23 05:18PM	Why Bluebird Bio Stock Soared 7% Higher on Tuesday (Motley Fool) +7.27%
08:00AM	Bluebird Bio Inc (BLUE) Reports Q3 2023 Financial Results: Strong Commercial Launch and ... (GuruFocus.com)
07:46AM	Bluebird Bio Q3 Loss Narrows, Tops Estimates; Revenues Miss Estimates (RTT News)
07:27AM	Bluebird: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	bluebird bio Reports Third Quarter 2023 Financial Results and Highlights Operational Progress (Business Wire)
Nov-04-23 08:45AM	Is Bluebird Bio Stock a Buy? (Motley Fool)
Nov-02-23 09:37AM	bluebird bio to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition (Business Wire)
Oct-30-23 08:00AM	bluebird bio Enters into Advance Agreement to Sell Priority Review Voucher, if Granted, for $103 Million (Business Wire)
Oct-24-23 08:00AM	bluebird bio to Host Third Quarter 2023 Financial Results Conference Call (Business Wire)
Oct-17-23 09:47AM	Dollar Tree upgraded, Microsoft initiated: Wall Street's top analyst calls (The Fly)
Sep-29-23 09:00AM	Where Will Bluebird Bio Be in 1 Year? (Motley Fool)
Sep-20-23 07:21AM	Better Growth Stock: CRISPR Therapeutics vs. Bluebird Bio (Motley Fool)
Sep-12-23 07:00AM	More Likely to 5x First: Bluebird Bio vs. CRISPR Therapeutics (Motley Fool)
05:14AM	2 Growth Stocks That Could Rocket 88% to 99% Higher According to Wall Street (Motley Fool)
Sep-07-23 11:30AM	Bluebird (BLUE) Up 7.3% Since Last Earnings Report: Can It Continue? (Zacks) -7.11%
Sep-05-23 04:05PM	bluebird bio Announces September Investor Events (Business Wire)
Aug-29-23 05:25AM	Is Bluebird Bio a Bargain Buy in September? (Motley Fool)
Aug-28-23 08:30AM	Wall Street Thinks This Tiny Biotech Company Could Soar Soon (Motley Fool)
Aug-24-23 10:15AM	1 Beaten-Down Growth Stock You'd Regret Not Buying on the Dip, According to Wall Street (Motley Fool)
Aug-16-23 07:00AM	bluebird bio Confirms That FDA Has Communicated That Advisory Committee Meeting Will Not Be Scheduled for lovo-cel Gene Therapy for Sickle Cell Disease (Business Wire)
Aug-08-23 08:25AM	Bluebird Bio (BLUE) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +8.06%
07:18AM	Bluebird: Q2 Earnings Snapshot (AP Finance)
07:00AM	bluebird bio Reports Second Quarter 2023 Financial Results and Highlights Operational Progress (Business Wire)
07:00AM	2 Magnificent Growth Stocks I'm Buying Hand Over Fist Right Now (Motley Fool)
Aug-05-23 09:40AM	1 Beaten-Down Stock That Could Soar by 89%, According to Wall Street (Motley Fool)
Jul-27-23 11:19AM	Bank of America Says These 2 Stocks Could Double Your Money Heres Why They Could Rally (TipRanks) -5.81%
Jul-25-23 08:00AM	bluebird bio to Host Second Quarter 2023 Financial Results Conference Call and Provide Commercial Update (Business Wire)
Jul-22-23 06:14AM	3 Small-Cap Stocks That Could Be Big-Time Winners (Motley Fool)
Jul-20-23 01:14AM	4 big analyst picks: AMD called a 'Top Pick' at Wolfe; Cisco upped at JPMorgan (Investing.com)
Jul-19-23 12:36PM	Why Bluebird Bio Stock Is Taking Flight Today (Motley Fool) +16.51%
Jun-30-23 10:15AM	Down 51% in 2023, Here's Why Bluebird Bio Stock Could Soon Double, Says Wall Street (Motley Fool)
Jun-29-23 09:53AM	This 1 Problem Could Sink at Least 4 Gene-Editing Stocks (Motley Fool) -5.01%
07:45AM	Is Bluebird Bio Stock a Buy Now? (Motley Fool)
Jun-21-23 07:00AM	bluebird bio Announces FDA Priority Review of the Biologics License Application for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusive Events (Business Wire)
Jun-15-23 10:00AM	2 Short-Squeeze Candidates That Could Go Parabolic (Motley Fool)
Jun-08-23 11:30AM	Bluebird (BLUE) Down 26% Since Last Earnings Report: Can It Rebound? (Zacks)
Jun-01-23 02:09AM	4 big analyst picks: Avis Budget zooms higher on Deutsche upgrade (Investing.com) +5.67%
May-10-23 07:57AM	Will bluebird bio (NASDAQ:BLUE) Spend Its Cash Wisely? (Simply Wall St.)
May-09-23 07:10AM	Bluebird: Q1 Earnings Snapshot (AP Finance) +12.64%
07:00AM	bluebird bio Reports First Quarter 2023 Financial Results and Highlights Operational Progress (Business Wire)
Apr-27-23 04:05PM	bluebird bio Announces First Quarter 2023 Earnings Date and Upcoming Investor Events (Business Wire)
Apr-24-23 03:49PM	With FDA Submission For Sickle Cell Gene Therapy, Bluebird Bio Can Potentially Have 3 Approved Products By 2023 (Benzinga)
07:30AM	bluebird bio Submits Biologics License Application (BLA) to FDA for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusive Events (Business Wire)

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Obenshain Andrew	President and CEO	Mar 04 '24	Sale	1.53	6,095	9,311	279,998	Mar 05 05:40 PM
Klima Thomas J	See Remarks	Mar 04 '24	Sale	1.53	4,573	6,986	124,840	Mar 05 05:39 PM
Colvin Richard A	Chief Medical Officer	Mar 01 '24	Sale	1.53	6,770	10,342	118,368	Mar 05 05:40 PM
Vittiglio Joseph	Chief Business & Legal Officer	Feb 05 '24	Sale	0.90	5,217	4,708	44,783	Feb 06 04:07 PM
Klima Thomas J	See Remarks	Feb 05 '24	Sale	0.90	2,714	2,449	129,413	Feb 06 04:07 PM
Obenshain Andrew	President and CEO	Feb 05 '24	Sale	0.90	1,879	1,696	286,093	Feb 06 04:07 PM
Obenshain Andrew	President and CEO	Jan 05 '24	Sale	1.43	3,162	4,520	287,972	Jan 09 04:05 PM
Colvin Richard A	Chief Medical Officer	Jan 05 '24	Sale	1.42	597	845	125,138	Jan 09 04:05 PM
Krawtschuk Christopher	Chief Financial Officer	Dec 06 '23	Sale	4.52	4,526	20,437	45,474	Dec 08 04:42 PM
Obenshain Andrew	President and CEO	Nov 03 '23	Sale	3.17	807	2,555	291,134	Nov 03 04:10 PM
Colvin Richard A	Chief Medical Officer	Nov 02 '23	Sale	2.98	2,343	6,975	125,735	Nov 03 04:10 PM
Klima Thomas J	See Remarks	Sep 05 '23	Sale	3.79	922	3,493	132,127	Sep 06 04:30 PM
Obenshain Andrew	President and CEO	Aug 10 '23	Sale	3.54	16,929	59,956	291,941	Aug 10 05:00 PM
Klima Thomas J	See Remarks	Jun 02 '23	Sale	3.50	4,130	14,451	133,049	Jun 06 04:06 PM

Open in Screener

FNCH

Finch Therapeutics Group Inc

May 17 • 04:00PM ET

1.94

Dollar change +0.02
Percentage change 1.04	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VXF VTI

Index	-	P/E	-	EPS (ttm)	-10.14	Insider Own	66.31%	Shs Outstand	1.61M	Perf Week	-3.48%
Market Cap	3.12M	Forward P/E	-	EPS next Y	-	Insider Trans	-0.90%	Shs Float	0.54M	Perf Month	-17.80%
Income	-16.28M	PEG	-	EPS next Q	-	Inst Own	8.51%	Short Float	4.88%	Perf Quarter	-22.40%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	111.80%	Short Ratio	0.50	Perf Half Y	-48.54%
Book/sh	11.86	P/B	0.16	EPS next Y	-	ROA	-25.22%	Short Interest	0.03M	Perf Year	-82.11%
Cash/sh	12.89	P/C	0.15	EPS next 5Y	41.70%	ROE	-62.64%	52W Range	1.86 - 16.74	Perf YTD	-46.26%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-37.86%	ROI	-34.95%	52W High	-88.41%	Beta	0.44
Dividend TTM	-	Quick Ratio	6.05	Sales past 5Y	-16.71%	Gross Margin	-1320.56%	52W Low	4.30%	ATR (14)	0.26
Dividend Ex-Date	-	Current Ratio	6.05	EPS Y/Y TTM	89.49%	Oper. Margin	0.00%	RSI (14)	42.23	Volatility	7.17% 10.94%
Employees	1	Debt/Eq	1.55	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	10.00
Option/Short	No / Yes	LT Debt/Eq	1.45	EPS Q/Q	93.95%	Payout	-	Rel Volume	0.18	Prev Close	1.92
Sales Surprise	-	EPS Surprise	-1377.78%	Sales Q/Q	-100.00%	Earnings	-	Avg Volume	52.92K	Price	1.94
SMA20	-12.31%	SMA50	-19.70%	SMA200	-49.61%	Trades		Volume	9,292	Change	1.04%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-09-22	Initiated	H.C. Wainwright	Buy	$17
Apr-13-21	Initiated	Jefferies	Buy	$29
Apr-13-21	Initiated	Evercore ISI	Outperform	$34
Apr-13-21	Initiated	BofA Securities	Buy	$25

May-13-24 10:54AM	FNCH Stock Earnings: Finch Therapeutics Gr Reported Results for Q1 2024 (InvestorPlace) -6.47%
Mar-25-24 09:52PM	FNCH Stock Earnings: Finch Therapeutics Gr Reported Results for Q4 2023 (InvestorPlace) +5.06%
Nov-22-23 09:14AM	Billionaire Seth Klarmans Biotech Stock Picks (Insider Monkey)
Jun-09-23 07:00AM	Finch Announces Reverse Stock Split of Common Stock (GlobeNewswire)
May-11-23 05:05AM	The Petri Dish: Laronde CEO exits after 6 months; Enanta seeks Covid pill partner (American City Business Journals) -5.06%
07:00AM	Loading…
May-10-23 07:00AM	Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire) -5.95%
Apr-25-23 04:05PM	Finch Therapeutics Announces Executive Leadership Transitions (GlobeNewswire) -9.94%
Apr-18-23 04:01PM	Finch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Womens Hospital and Updates to University of Minnesota License Agreement (GlobeNewswire)
Mar-25-23 09:34AM	Finch Therapeutics Group Full Year 2022 Earnings: Misses Expectations (Simply Wall St.)
Mar-23-23 04:05PM	Finch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Jan-24-23 01:53PM	Microbiome startup cuts 95% of remaining staff in 3rd layoff in 9 months (American City Business Journals)
10:55AM	Finch Therapeutics Halts Work On Its Only Clinical Stage Asset, Cuts 95% Of Workforce (Benzinga)
08:00AM	Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets (GlobeNewswire)
Nov-10-22 08:15AM	Finch Therapeutics Group, Inc. (FNCH) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Finch Therapeutics Provides Corporate Updates and Reports Third Quarter 2022 Financial Results (GlobeNewswire)
08:00AM	Loading…
Nov-09-22 08:00AM	Finch Therapeutics to Present at the Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference (GlobeNewswire) -5.09%
Oct-24-22 08:00AM	Finch Therapeutics Presents PRISM-EXT Biomarker Data at ACG 2022 and Proceeds with Patient Dosing in Phase 3 Trial of CP101 in Recurrent C. Difficile Infection (GlobeNewswire) +14.07%
Sep-05-22 12:00PM	Finch Therapeutics Group, Inc. (FNCH) Upgraded to Buy: Here's Why (Zacks)
Sep-01-22 02:23PM	After Takeda ends collaboration, microbiome startup Finch Therapeutics cuts 50 jobs (American City Business Journals)
08:00AM	Finch Therapeutics Provides Business Update (GlobeNewswire)
05:32AM	The Petri Dish: Takeda ends Finch deal, Bain buys Waltham manufacturer (American City Business Journals)
Aug-26-22 07:37AM	After Six Years Of Collaboration, Takeda Walks Away From Microbiome Drug Pact (Benzinga) -5.77%
Aug-25-22 04:30PM	Finch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Microbiome Product Candidates in Development for IBD (GlobeNewswire) +8.70%
Aug-11-22 07:00AM	Finch Therapeutics Provides Corporate Updates and Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-10-22 08:06AM	Here's Why We're Watching Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Situation (Simply Wall St.) +5.26%
Jul-20-22 09:48AM	As Finch Therapeutics Group, Inc. (NASDAQ:FNCH) drops to US$103m market cap, insiders might rethink their US$650k stock purchase earlier this year (Simply Wall St.)
Jun-02-22 07:00AM	Finch Therapeutics to Participate in Upcoming June Investor Conferences (GlobeNewswire)
May-17-22 08:00AM	Finch Therapeutics to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) +10.75%
May-16-22 07:00AM	Finch Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results (GlobeNewswire)
May-09-22 08:22AM	Finch Therapeutics to Host Corporate Update Conference Call and Webcast on May 16, 2022 (GlobeNewswire) -10.04%
12:10PM	Loading…
Apr-29-22 12:10PM	Why Finch Therapeutics Stock Is Skyrocketing Today (Motley Fool) +20.48%
Apr-28-22 05:20PM	Finch Therapeutics Announces Removal of FDA Clinical Hold on CP101 IND (GlobeNewswire) -7.49%
Apr-20-22 12:33PM	Finch Therapeutics Cuts 20% Workforce, Realigns Focus On C. Diff, Autism Programs (Benzinga) -6.28%
Apr-19-22 02:08PM	Finch cuts one-fifth of staff amid Hep B program pause (American City Business Journals)
08:30AM	Finch Therapeutics Announces Workforce Restructuring to Focus Resources on Key Development Programs (GlobeNewswire)
Mar-31-22 04:56PM	Finch Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-19-22 08:04AM	Shareholders in Finch Therapeutics Group (NASDAQ:FNCH) are in the red if they invested a year ago (Simply Wall St.)
Mar-01-22 04:30PM	Finch Therapeutics Provides an Update on its Phase 3 Trial of CP101 in Recurrent C. difficile Infection (GlobeNewswire)
Feb-23-22 07:00AM	Finch Therapeutics to Participate in the Chardan Metagenomics and Microbiome Medicines Summit (GlobeNewswire)
Feb-10-22 07:00AM	Finch Therapeutics Announces Additions to Senior Leadership Team (GlobeNewswire) -6.87%
Jan-18-22 05:38PM	First Midwest Bank Trust Division Buys Axsome Therapeutics Inc, PROSHARES TRUST, iShares ... (GuruFocus.com)
Jan-06-22 07:00AM	Finch Therapeutics Further Strengthens Patent Portfolio with Two New U.S. Patents Granted for FIN-211, an Investigational Microbiome Therapeutic in Development for Autism Spectrum Disorder (GlobeNewswire)
Jan-04-22 07:00AM	Finch Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright BioConnect Conference (GlobeNewswire)
Dec-23-21 04:38AM	Trade Alert: The Independent Director Of Finch Therapeutics Group, Inc. (NASDAQ:FNCH), Nicholas Haft, Has Just Spent US$650k Buying 1.6% More Shares (Simply Wall St.) +15.77%
Dec-20-21 07:00AM	Finch Therapeutics Appoints Joseph Vittiglio, JD, as Chief Business and Legal Officer (GlobeNewswire) +8.16%
Dec-17-21 06:31AM	We're Keeping An Eye On Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Rate (Simply Wall St.) -8.11%
Nov-11-21 07:00AM	Finch Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.61%
Nov-10-21 07:15AM	Finch Therapeutics' C. Difficile Infection Candidate Meets Primary Goal In Mid-Stage Study (Benzinga)
07:05AM	Finch Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates (GlobeNewswire)
07:00AM	Finch Therapeutics Announces Transition of Chief Medical Officer (GlobeNewswire)
Nov-09-21 04:30PM	Finch Therapeutics Announces Positive Topline Results from PRISM-EXT Phase 2 Trial of CP101 for Prevention of Recurrent C. difficile Infection (GlobeNewswire) +5.72%
Oct-25-21 07:00AM	Finch Therapeutics Presents Positive Data from PRISM3 Clinical Trial of CP101 for Recurrent C. difficile at American College of Gastroenterology Annual Scientific Meeting (GlobeNewswire) +6.89%
Oct-18-21 08:58AM	What Type Of Shareholders Make Up Finch Therapeutics Group, Inc.'s (NASDAQ:FNCH) Share Registry? (Simply Wall St.)
Oct-12-21 07:00AM	Finch Therapeutics to Present at the Jefferies Virtual Next Generation IBD Therapeutics Summit (GlobeNewswire)
Oct-05-21 07:00AM	Finch Therapeutics Appoints Samuel Allen Hamood to its Board of Directors (GlobeNewswire)
Sep-08-21 07:00AM	Finch Therapeutics Announces the Appointment of Marc Blaustein as Chief Operating Officer (GlobeNewswire)
Sep-07-21 07:00AM	Finch Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
Aug-18-21 08:54AM	Insiders might want to re-evaluate their US$42m stock purchase as Finch Therapeutics Group, Inc. (NASDAQ:FNCH) drops to US$606m (Simply Wall St.)
Aug-10-21 03:54PM	Takeda To Lead Finch-Partnered Microbiome IBD Drug (Benzinga)
07:05AM	Finch Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire)
07:00AM	Finch Therapeutics Announces Takeda to Accelerate Leadership Role in FIN-524 Ulcerative Colitis Development Program (GlobeNewswire)
Jun-28-21 07:00AM	Finch Therapeutics Added to Russell 2000 and Russell 3000 Indexes (GlobeNewswire)
May-28-21 07:00AM	Finch Therapeutics to Present at Upcoming Virtual Investor Conferences (GlobeNewswire) -5.26%
May-13-21 07:00AM	Finch Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates (GlobeNewswire)
May-06-21 07:00AM	Finch Therapeutics to Participate in the BofA Securities 2021 Virtual Health Care Conference (GlobeNewswire)
Apr-27-21 07:00AM	Finch Therapeutics Appoints Susan E. Graf to Board of Directors (GlobeNewswire)
Mar-19-21 04:25PM	Three Biotechs, plus a Marijuana Lender, Open for Trading (Barrons.com)
Mar-18-21 10:32PM	Finch Therapeutics Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Finch Therapeutics Group, Inc. engages in the development of microbiome drugs. Its platform includes Human-First Discovery that enables reverse translation from clinical data to engineer the composition of the microbiome based on disease-modifying mechanisms. The company was founded by Mark Smith, Andrew Noh, Tom Borody and Zain Kassam in 2014 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SMISEK JEFFERY A	Director	Mar 28 '24	Sale	2.57	6,642	17,070	0	Mar 29 04:15 PM
SMISEK JEFFERY A	Director	Mar 28 '24	Sale	2.61	1,600	4,176	6,512	Mar 29 04:15 PM
SMISEK JEFFERY A	Director	Nov 22 '23	Sale	3.64	1,470	5,351	6,642	Nov 27 04:54 PM
Graf Susan E	Director	Jun 09 '23	Buy	0.27	5,010	1,353	5,010	Jun 09 04:15 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

BLUE

Bluebird bio Inc

FNCH

Finch Therapeutics Group Inc

Upgrade your FINVIZ experience